MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-21
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
203
Registration Number
NCT00210769

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Phase 3
Completed
Conditions
Anemia
Breast Neoplasms
Quality of Life
First Posted Date
2005-09-21
Last Posted Date
2010-11-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
939
Registration Number
NCT00211133

A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children

Phase 3
Completed
Conditions
Vascular Headaches
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
110
Registration Number
NCT00210535

A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-21
Last Posted Date
2010-11-19
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
273
Registration Number
NCT00210691

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

Completed
Conditions
Musculoskeletal Diseases
Interventions
First Posted Date
2005-09-21
Last Posted Date
2014-04-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
2233
Registration Number
NCT00210639

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

Completed
Conditions
Red-Cell Aplasia, Pure
First Posted Date
2005-09-21
Last Posted Date
2015-07-31
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
4670
Registration Number
NCT00211029

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2
Terminated
Conditions
Aged
Hemoglobins
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
12
Registration Number
NCT00210795

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
First Posted Date
2005-08-22
Last Posted Date
2013-07-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
559
Registration Number
NCT00132678

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-07-14
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
253
Registration Number
NCT00119756

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

Phase 3
Completed
Conditions
Partial Seizure Disorder
Epilepsy
Seizures
Interventions
Drug: placebo
First Posted Date
2005-06-13
Last Posted Date
2014-03-26
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
118
Registration Number
NCT00113815
© Copyright 2025. All Rights Reserved by MedPath